Rapid Improvement of Disseminated Intravascular Coagulation by Donor Leukocyte Infusions in a Patient with Promyelocytic Crisis of Chronic Myelogenous Leukemia after Reduced-Intensity Stem Cell Transplantation from an HLA 2-Antigen—Mismatched Mother

2003 ◽  
Vol 77 (4) ◽  
pp. 408-411 ◽  
Author(s):  
Kosei Matsue ◽  
Konagi Yamada ◽  
Masami Takeuchi ◽  
Takayuki Tabayashi
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Chronic Myelogenous Leukemia ◽  
Disseminated Intravascular Coagulation ◽  
Myelogenous Leukemia ◽  
Rapid Improvement ◽  
Intravascular Coagulation ◽  
Reduced Intensity

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4838-4838
Author(s):  
Guillermo J. Ruiz-Arguelles ◽  
David Gomez-Almaguer ◽  
Amelia Morales-Toquero ◽  
Cesar H. Gutierrez-Aguirre ◽  
Jorge Vela-Ojeda ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Median Time ◽  
Chronic Myelogenous Leukemia ◽  
Latin American ◽  
Chronic Gvhd ◽  
Chronic Phase ◽  
Myelogenous Leukemia ◽  
Reduced Intensity

Abstract Using a reduced intensity stem cell transplantation (RIST) schedule, 24 patients with Ph1 (+) chronic myelogenous leukemia (CML) in first chronic phase were prospectively allografted in four Latin American countries: Mexico, Brasil, Colombia and Venezuela, using HLA-identical siblings as donors. Median age of the patients was 41 years (range 10 to 71); there were 8 females. Patients received a median of 4.4 x 106/ Kg CD34 cells. Median time to achieve above 0.5 x 109/L granulocytes was 12 days, range 0–41, whereas median time to achieve above 20 x 109/L platelets was also 12 days, range 0–45. Twenty two patients are alive 81 to 830 (median 497) days after the RIST. The 830-day probability of survival is 92%, whereas median survival has not been reached, being above 830 days. Eleven patients (46%) developed acute graft versus-host disease (GVHD), whereas 7 of 23 (30%) developed chronic GVHD. Two patients died 43 and 210 days after the RIST, one as a result of sepsis and the other one of chronic GVHD. The 100-day mortality was 4.4 %, whereas the transplant-related mortality was 8%. RIST for patients with CML in chronic phase seems as an adequate therapeutic option.

Sign in / Sign up

Export Citation Format

Share Document